Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Articles, Abstracts, and Reports
1-1-2017

Interpretation of positive troponin results among patients with
and without myocardial infarction.
Kristen M Tecson
William Arnold
Tyler Barrett
Robert Birkhahn
Lori B Daniels

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Cardiology Commons

Authors
Kristen M Tecson, William Arnold, Tyler Barrett, Robert Birkhahn, Lori B Daniels, Christopher DeFilippi, Gary
Headden, W Frank Peacock, Michael Reed, Adam J Singer, Jeffrey M Schussler, Stephen Smith, Martin P
Than, and Peter A McCullough

Interpretation of positive troponin results among patients
with and without myocardial infarction
Kristen M. Tecson, PhD, William Arnold, PhD, Tyler Barrett, MD, Robert Birkhahn, MD, Lori B. Daniels, MD,
Christopher DeFilippi, MD, Gary Headden, MD, W. Frank Peacock, MD, Michael Reed, MD, Adam J. Singer, MD,
Jeffrey M. Schussler, MD, Stephen Smith, MD, Martin P. Than, MD, and Peter A. McCullough, MD, MPH

Measuring cardiac troponins is integral to diagnosing acute myocardial
infarction (AMI); however, troponins may be elevated without AMI,
and the use of multiple different assays confounds comparisons. We
considered characteristics and serial troponin values in emergency
department chest pain patients with and without AMI to interpret
troponin excursions. We compared serial troponin in 124 AMI and
non-AMI patients from the observational Performance of Triage Cardiac
Markers in the Clinical Setting (PEARL) study who presented with chest
pain and had at least one troponin value exceeding the 99th percentile
of normal. Because 8 assays were used during data collection, we
employed a method of scaling the troponin value to the corresponding assay’s 99th percentile upper reference limit to standardize the
results. In 81 AMI patients, 96% had elevated troponin at the first test
following initial elevation, compared to 73% of the 43 non-AMI patients
(P < 0.001). Scaling troponin to the 99th percentile of normal yielded
a median value that was 4.8 [2.2, 14.1] times higher than the 99th
percentile cutpoint among AMI patients, compared to 2.3 [1.5, 6.5]
times higher among non-AMI patients (P = 0.04). The rise in serial
scaled troponin values distinguished the AMI patients. Scaling to the
99th percentile was useful for comparing troponin when different
assays were utilized.

H

igh-sensitivity troponin I testing has been shown to
improve the early diagnosis of acute myocardial infarction (AMI) and aid with risk stratiﬁcation (1–3).
Investigators using a registry in Australia and New
Zealand determined that high-sensitivity troponin I testing
was associated with fewer in-hospital adverse events for patients hospitalized with possible acute coronary syndrome
(4). There are multiple non-AMI clinical scenarios, however,
where troponin may exceed the 99th percentile, including
renal failure, stroke, heart failure, pulmonary embolism, sepsis,
and hypertension (5). We capitalized on a data set of chest
pain patients who had serial troponin assays performed, had
at least one positive value, and had central adjudication of
the outcome of AMI. We compared the characteristics, as
well as the dynamic rise and fall of troponin, in this group
of patients to better understand how to quantitatively evaluate the excursion of troponin and relate it to the conﬁrmed
diagnosis of AMI.
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METHODS
We performed retrospective analyses on data collected from
a prospective, multicenter, observational study (Performance
of Triage Cardiac Markers in the Clinical Setting [PEARL])
that examined the use of troponin for the diagnosis of AMI
in patients ≥21 years of age who presented to the emergency
department with symptoms of possible AMI from August 2014
through February 2015. Patients with symptoms including
sharp or dull chest pain, tightness, sensations of heavy weight
on the chest, pain in the jaw or neck, pain radiating down the
arms, and dyspnea were monitored for approximately 24 hours.
A team of 3 experienced adjudicators (1 emergency physician
and 2 cardiologists) independently reviewed case report forms
and the 12-lead electrocardiogram recorded during initial evaluation plus at least one additional electrocardiogram if obtained
in the subject evaluation period to form a diagnosis of AMI
or non-AMI using contemporary guideline deﬁnitions (6).
Discrepancies were discussed until consensus was reached. All
institutions received institutional review board approval and
patients’ informed consent prior to conducting this study.
Troponin was evaluated using one of the following tests:
Abbott ARCHITECT STAT TnI (7), Abbott i-STAT® POC
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cTnI (8), Alere Triage® POC cTnI (9), Beckman Coulter
Access® AccuTnI®+3 (10), Ortho VITROS® TnI ES (11),
Roche Cobas® TnT (12), Siemens ADVIA Centaur® TnI-Ultra
(13), or Siemens Dimension Vista® TnI (14). These tests yielded
results in diﬀerent measurable ranges with unique 99th percentile cutpoints. For that reason, we treated the data in two ways.
First, we dichotomized the results as being either elevated or not
elevated based on the 99th percentile cutoﬀ rules for each assay.
Second, to standardize the many troponin assays, we scaled the
results using the ratio of the observed troponin value divided
by the 99th percentile upper reference limit (“normal” value)
(15). For example, a patient with a troponin value of 0.1 ng/mL
using the Roche Cobas® TnT, which has a 99th percentile upper reference limit of 0.01 ng/mL, would have a scaled result
of 0.1/0.01 = 10. We interpret this as a troponin value that is
10 times that of the 99th percentile of normal. We considered
results from both methods across the sequence of troponin tests
following the initial elevated result.
Continuous variables are reported as medians [quartile 1,
quartile 3], and categorical variables are reported as frequencies
(percent). Diﬀerences between diagnosis groups were tested
using Fisher’s exact test, 2-sample t test, or Wilcoxon rank sum
test, as appropriate. All analyses were conducted using SAS
9.4, Cary, NC.
RESULTS
A total of 458 patients enrolled in the PEARL study from
8 facilities. Of the 458 patients, 20 withdrew during the observation period, leaving a total of 438 patients who received an
adjudicated diagnosis. There were 1179 total troponin values,
391 (33%) of which were greater than the corresponding 99th
percentile upper reference limit. A total of 124 (28%) of the
438 patients had at least one elevated troponin level and are
the focus of this article. Eighty-one (65%) of the 124 patients
were adjudicated as AMI and the remaining 43 (35%) as nonAMI. Among these 124 patients, the AMI group was more
likely to have previously known coronary artery disease than
the non-AMI group (57% and 31%, respectively; P = 0.008).
Conversely, the AMI group was less likely to have renal failure
compared to the non-AMI group (5% and 35%, respectively;
P < 0.001). Sample characteristics for the 124 patients with
elevated troponin appear in Table 1.
The median time from arrival to ﬁrst elevated troponin was
1.17 [0.70, 3.25] hours for AMI patients and 0.97 [0.60, 4.13]
hours for non-AMI patients (P = 0.08) (Figure 1). Additionally, the median time between the ﬁrst elevated troponin and
subsequent test was 3.79 [2.25, 6.77] hours for AMI patients
and 3.80 [2.25, 5.70] hours for non-AMI patients (P = 0.81).
Similarly, the median times between the ﬁrst and second test
following the initial elevation, as well as the second and third
test following the initial elevation, did not diﬀer (P = 0.95
and 0.37, respectively). The median number of troponin tests
performed per patient until the ﬁrst elevation occurred was 1
for both AMI and non-AMI patients; however, the median
total number of tests performed for AMI patients was 4 [3, 5],
compared to 3 [2, 4] for non-AMI patients (P = 0.01).
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Table 1. Study sample characteristics
Acute myocardial infarction
Variable

Yes (n = 81)

No (n = 43) P value

Age (years)

58.6 ± 11.1

57 ± 16.7

0.58

56 (69%)

28 (65%)

0.69

Men
Race
Black
Asian

0.05
18 (22%)
0

17 (40%)
1 (2%)

White

56 (69%)

21 (51%)

Other

7 (9%)

4 (9%)

Atrial fibrillation

10 (12%)

6 (14%)

0.78

Alcohol

15 (19%)

5 (12%)

0.44

Arthritis

7 (9%)

4 (9%)

1.00

Asthma

6 (7%)

8 (19%)

0.08

Coronary artery disease

46 (57%)

13 (31%)

0.008

Cancer

13 (16%)

6 (14%)

1.00

1 (1%)

1 (2%)

1.00

Constipation
Chronic obstructive pulmonary disease

10 (12%)

4 (10%)

0.77

Diabetes

21 (26%)

18 (42%)

0.10

Emphysema

2 (3%)

1 (2%)

1.00

Gallstone

2 (3%)

0

0.54

Hepatitis

2 (3%)

3 (7%)

0.34

Liver cirrhosis

1 (1%)

0

1.00

Systemic lupus erythematosus

1 (1%)

1 (2%)

1.00

Migraine

0

2 (5%)

0.12

Peripheral artery disease

4 (5%)

3 (7%)

0.69

Renal failure

4 (5%)

15 (35%)

<0.001

Seizure

1 (1%)

3 (7%)

0.12

Smoke

43 (53%)

17 (41%)

0.25

Stroke

1 (1%)

3 (7%)

0.12

Transient ischemic attack

2 (3%)

3 (7%)

0.34

Figure 1. Hours from arrival at the emergency department to the first elevated
troponin result by myocardial infarction diagnosis.

Baylor University Medical Center Proceedings

Volume 30, Number 1

Figure 3. Median scaled troponin by diagnosis group and lab draw sequence.

Figure 2. Rates of troponin elevation by diagnosis group and lab draw sequence.

Of the 124 patients who had at least one elevated troponin,
114 (91.9%) had at least one subsequent test performed. Among
the 77 retested AMI patients, 74 (96.1%) were conﬁrmed to
have elevated troponin on the following lab draw. In contrast,
only 27 (73.0%) of the 37 retested non-AMI patients had an
elevated result at the following test (P < 0.001) (Figure 2). After
the ﬁrst elevated troponin, a diﬀerence in the rate of elevation was not observed between AMI and non-AMI patients on
the second or third subsequent lab draws (P = 0.60 and 0.31,
respectively).
When considered as a continuous variable scaled to the
99th percentile upper reference limit, we observed a median
troponin that was 4.8 [2.2, 14.1] times higher than the upper
limit of normal among AMI patients, compared to a median 2.3
[1.5, 6.5] times higher than the upper limit of normal among
non-AMI patients (P = 0.04). The AMI group’s median troponin during the ﬁrst test following the initial elevation was
10.2 [3.4, 73.3] times that of normal compared to 2.0 [0.9,
5.5] times that of normal for the non-AMI group (P < 0.001).
Further, the median paired diﬀerence between patients’ initial elevated troponin and subsequent test was 4.1 [0.1, 39.7]
for AMI patients and –0.2 [–1.6, 0.5] for non-AMI patients
(P < 0.001). Additionally, the median scaled troponin was 16.7
[4.3, 95.3] for AMI patients on the second lab draw following
the initial elevated result, compared to 3.3 [2.0, 16.7] for nonAMI patients (P = 0.002). Finally, the median scaled troponin
was 18.8 [4.0, 49.6] for AMI patients on the third lab draw
following the initial elevation compared to 4.6 [2.1, 18.6] for
non-AMI patients (P = 0.03). To verify that these ﬁndings were
not driven by an uneven utilization of assays between AMI and
non-AMI patients, we conducted chi-square tests and conﬁrmed
that there were no signiﬁcant diﬀerences between the groups’
assays at any of the four lab draws analyzed (P values = 0.30,
0.31, 0.44, 0.07). The diﬀerences and rates of change in median
scaled troponin for AMI and non-AMI patients are shown in
Figure 3 and Figure 4, respectively.
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DISCUSSION
Among 124 emergency department patients who presented
with chest discomfort and at least one positive troponin value
using contemporary sensitivity assays, 65.3% were conﬁrmed
to have AMI by an independent adjudication panel. Ninety-six
percent of the AMI patients had conﬁrmatory elevated troponins upon serial testing in the emergency department. Use of the
99th percentile cutpoint of normal and scaling of the elevation
to that anchor provided clear diﬀerences in the excursions of
troponin between those with and without AMI.
Our analyses provide a response to the criticisms regarding the high rate of false-positive cases generated as a result of
considering the 99th percentile cutoﬀ as positive or negative
on single tests (16, 17). Considering the change in serial values
of troponin concentration scaled to the 99th percentile has
previously been shown as superior to the 99th percentile cutoﬀ
alone (18). After performing these analyses, we also considered
the diﬀerences in raw troponin values between AMI and nonAMI patients at the 4 timepoints and found that they were in
agreement with the scaled results (P = 0.006, <0.001, <0.0001,
0.04). Although using the raw and scaled values yielded similar
statistical results, the conclusions drawn with the raw values
were far more confounded due to the use of several assays,

Figure 4. Rates of change in median scaled troponin by diagnosis.
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whereas the scaled values oﬀered a standardized interpretation,
regardless of assay.
We found that the ﬁrst troponin test alone was not sufﬁciently informative, nor was it elevated at an earlier time in
those diagnosed as AMI or non-AMI. There was a quantitative
diﬀerence in the rate of troponin elevation at the ﬁrst test following initial elevation; however, a signiﬁcant diﬀerence in the
rates of troponin elevation was not observed in the second and
third subsequent draws following the initial elevation among
AMI and non-AMI patients. This was likely attributed to the
diﬀering rates of clinically driven retesting within each group
over time. For example, only 23 (53.5%) patients without an
AMI were tested ≥2 times after the initial elevation, compared
to 67 (82.7%) of those retested with an AMI. This was not surprising because AMI patients were more likely to have a history
of coronary artery disease pointing to a higher clinical suspicion
and a more assiduous approach to the diagnosis of AMI.
Although we did not observe signiﬁcant diﬀerences in dichotomized rates of troponin elevation at every lab draw, we did
observe higher median scaled troponin values in AMI patients
compared to non-AMI patients. As shown in Figure 3, the gradient of the troponin line sharply increased for those with AMI,
while the line for those without AMI was relatively ﬂat. This
indicated that those with AMI had true ischemic rises, while
those without AMI had slight elevations in troponin attributed
to other causes. These results conﬁrmed the ﬁndings of a previous study, which suggested that the method of scaling troponin
in terms of the 99th percentile is viable (19). In another study,
patients with asymptomatic AMI (as diagnosed via electrocardiogram) were shown to have higher median high-sensitivity
troponin I values than patients who did not have an AMI (20).
Our results and those of others suggest that the interpretation
of the excursion of serial troponin rather than single troponin
values is critical in the diagnosis of AMI.
This work was a retrospective secondary analysis of an observational data cohort and is therefore subject to the inherent
limitations of such studies. The study enrolled via convenience
sample, so there is the potential for selection bias. We conducted
analyses based on many diﬀerent contemporary troponin assays, including troponin I and troponin T across a variety of
laboratory platforms. The multiplicity of testing was clinically
determined and was clearly biased by the physician’s suspicion of
AMI. Troponin testing provides no information to distinguish
between type 1 or type 2 myocardial infarction. Because this
analysis considered only those patients with elevated troponin,
our sample size was small, which limited the power and generalizability of the results. Finally, we recognize that our study results
may not generalize to populations with greater comorbidities,
including renal failure, sepsis, heart failure, and other illnesses,
where there may be greater proportions of troponin elevation
or greater diﬃculty in determining AMI (21–23).
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